CANCER JOURNAL is a leading peer-reviewed publication dedicated to the dissemination of innovative research in the fields of cancer research and oncology. Published by Lippincott Williams & Wilkins, this journal serves as an essential resource for researchers, clinicians, and students seeking to advance their understanding of cancer mechanisms, treatment strategies, and patient care. With an ISSN of 1528-9117 and an E-ISSN of 1540-336X, it boasts a respectable 2023 Q2 category ranking in both Cancer Research and Oncology, reflecting its impactful contributions to the scientific community. Although it currently does not offer open access, the journal's rigorous peer-review process ensures the publication of high-quality, relevant studies that stimulate further investigation and collaboration among professionals. Since its inception, the journal has evolved through several converged years, maintaining a steadfast commitment to addressing the complexities of cancer biology and treatment. At its core, CANCER JOURNAL aims to foster advancements in oncology, making it a vital platform for sharing pivotal findings that could transform cancer research and therapeutic practices.

LEUKEMIA & LYMPHOMA is a prestigious peer-reviewed journal published by Taylor & Francis Ltd, focusing on vital research in the fields of hematology, oncology, and cancer research. With an ISSN of 1042-8194 and an E-ISSN of 1029-2403, this journal is recognized for its high-quality and impactful contributions to understanding blood cancers, with a notable impact factor reflective of its influence. Since its inception in 1989, LEUKEMIA & LYMPHOMA has continuously provided a platform for researchers and professionals to disseminate their findings, fostering advancements in diagnostic, therapeutic, and clinical strategies related to leukemias and lymphomas. The journal ranks in the Q2 category for both Hematology and Oncology research categories as of 2023, underscoring its commitment to excellence. The journal is based in the United Kingdom and serves a global audience, making it an essential resource for those dedicated to improving outcomes for patients with hematological malignancies.

Gastric Cancer is a leading journal in the field of oncology, published by SPRINGER in Japan. With an ISSN of 1436-3291 and an E-ISSN of 1436-3305, this esteemed journal aims to disseminate high-quality research focused on all aspects of gastric cancer, including its pathophysiology, diagnosis, treatment, and prevention. As an indicator of its academic excellence, Gastric Cancer is ranked in the top quartile (Q1) for Cancer Research, Gastroenterology, Medicine (miscellaneous), and Oncology categories as of 2023. The journal holds impressive Scopus rankings, being positioned #9 in Gastroenterology and #34 in Oncology, demonstrating its critical role in shaping advancements within these disciplines. Although not an open-access publication, it provides various access options for institutions and individuals looking to elevate their understanding of gastric cancer. With a converged publication history from 2000 to 2024, it serves as a vital resource for researchers, professionals, and students dedicated to eradicating this formidable disease.

Blood and Lymphatic Cancer-Targets and Therapy, published by DOVE MEDICAL PRESS LTD, is a vital open-access journal that has been disseminating crucial research and findings in the field of hematology and oncology since 2011. With its ISSN 1179-9889, this journal focuses on the latest therapeutic targets and innovative treatment strategies for blood and lymphatic cancers, contributing significantly to the advancement of knowledge and practice in this specialized area. Designed for researchers, healthcare professionals, and students alike, Blood and Lymphatic Cancer-Targets and Therapy aims to foster a deeper understanding of cancer biology and promote collaborative efforts leading to novel therapeutic interventions. The open-access model ensures that research findings are readily accessible to a global audience, underscoring the journal's commitment to enhancing patient care and fostering educational growth in the cancer domain.

JCO Precision Oncology, published by Lippincott Williams & Wilkins, is a leading journal in the field of cancer research and oncology, recognized for its high-impact contributions and innovative approaches to precision medicine. Since its inception in 2017, this journal has consistently ranked in the Q1 category in both Cancer Research and Oncology for 2023, reflecting its esteemed position within the academic community. With a rigorous peer-review process and a focus on disseminating cutting-edge research, JCO Precision Oncology serves as a vital platform for researchers, clinicians, and healthcare professionals aiming to enhance the understanding and treatment of cancer through individualized therapies. The journal's comprehensive scope includes studies on genetic profiling, biomarker research, and novel therapeutic strategies, making it an essential resource for anyone involved in cancer care and research. Explore further and join a community committed to advancing precision oncology and improving patient outcomes.

Mediterranean Journal of Hematology and Infectious Diseases is a distinguished open access journal published by MATTIOLI 1885, dedicated to advancing the field of hematology and infectious diseases. Since its inception in 2009, the journal has provided a platform for researchers and practitioners to disseminate innovative findings, foster scholarly discourse, and enhance our understanding of these critical medical disciplines. With an impact factor reflecting its scholarly influence, it is recognized in the Q3 quartile for both Hematology and Infectious Diseases categories as of 2023. The journal's commitment to open access ensures that high-quality research is accessible to a global audience, contributing to the improvement of clinical practices and public health. Located in Fidenza, Italy, the journal continues to support converged research efforts from 2010 to 2024, making it an essential resource for academics, clinicians, and students in the medical community.

UHOD-Uluslararasi Hematoloji-Onkoloji Dergisi, published by AKAD DOKTORLAR YAYINEVI, is a pivotal journal in the fields of hematology and oncology, catering to an international audience of researchers, clinicians, and students. Since its inception in 2005, the journal has committed to disseminating high-quality, peer-reviewed research, highlighting advancements and challenges in the diagnosis and treatment of hematological and oncological disorders. Registered under ISSN 1306-133X, it serves as a significant platform for scholarly discourse, despite its recent categorization in the Q4 quartile for both hematology and oncology—indicating opportunities for growth and contribution within the scientific community. While currently not Open Access, the journal's indexed contribution to Scopus ranks it within the 12th and 17th percentiles in the domains of hematology and oncology respectively, reflecting its emerging presence within the academic landscape. As it approaches its convergence point in 2024, UHOD strives to elevate its influence, providing invaluable insights and fostering collaborations in the ongoing fight against blood disorders and cancer.

Leukemia Research is a prominent academic journal dedicated to advancing the field of hematology and oncology, focusing on the latest research developments related to leukemia and other hematological disorders. Founded in 1977 and published by Pergamon-Elsevier Science Ltd in the United Kingdom, this esteemed journal has established itself as a vital resource for researchers and clinicians alike. With an impressive impact factor and categorized in the top quartiles of Cancer Research and Hematology, it provides a platform for high-quality research articles, reviews, and clinical studies that contribute to a deeper understanding of leukemia's complexities. Although not an Open Access journal, Leukemia Research ensures widespread dissemination of knowledge crucial for developing innovative treatment strategies and improving patient outcomes. Researchers, professionals, and students in the fields of hematology and oncology will find this journal an invaluable asset in staying at the forefront of leukemia research, as it prepares to expand its impact through converged years of publication extending into 2024.

ANNALS OF HEMATOLOGY, published by Springer in Germany, stands as a premier platform for advancing knowledge in the field of hematology and medicine at large. With a significant impact factor and recognized rankings—Q2 in Hematology and Q1 in Medicine (miscellaneous) as of 2023—this journal is pivotal for researchers, clinicians, and students who are keen on exploring the latest developments in blood disorders, treatments, and innovative methodologies. Its broad scope encompasses original research, reviews, and discussions that aim to foster interdisciplinary dialogue, ensuring that the latest findings and theories are accessible to the scientific community. Although not an open-access journal, its rigorous peer-review process guarantees high-quality contributions, thereby solidifying its reputation as a vital resource in the hematological field. Founded in 1991, the ANNALS OF HEMATOLOGY continues to evolve, converging invaluable insights from both basic and clinical research until 2024. For those dedicated to improving patient outcomes and advancing hematological science, this journal remains an essential reference.

ACTA HAEMATOLOGICA, published by KARGER, is a prestigious journal established in 1948, dedicated to the field of hematology and related medical sciences. With an ISSN of 0001-5792 and an E-ISSN of 1421-9662, this journal stands out with a Q2 ranking in both Hematology and Miscellaneous Medicine categories as of 2023. Researchers and professionals can benefit from its high-quality peer-reviewed articles, contributing to a more profound understanding and advancement of hematological practices. Although it does not offer open access options, ACTA HAEMATOLOGICA remains an essential resource for researchers in Switzerland and worldwide, providing critical insights and fostering discourse among academic and clinical communities. The journal's address is located in the heart of Basel, Switzerland, ensuring its robust connection to European medical research networks. With a firm commitment to excellence, this publication plays a vital role in disseminating knowledge, guiding future innovations in the field.